Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs placebo in antidepressant-resistant major depression or dysthymic disorder (12-week, phase 2a)
2010-022744-21Phase 2Terminated
- Sponsor
- AB Science
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD), persistent depressive disorder (PDD) and affective disorder comparing Masitinib 4.5 mg/kg/day with Placebo (2 arms). Primary endpoints: Response rate, Proportion of responders at week 4 and 1 more. Started Mar 2013; status: terminated.
02
Drugs
masitinib
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)affective disorder
Beyond the preview
Go deeper on 2010-022744-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022744-21.